Clinical trials: in Mexico
COVID-19
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication.
- Trial name
- NCT05605093
- Testing
- Shionogi Protease Inhibitor (S-217622)
- Where
- 187 sites in United States, Argentina and 22 more
- Volunteers
- 602 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 2/Prevention & Control, Diabete Type 2
Therapeutic Adherence in Type 2 Diabetes
A quasi-experimental, non-randomized, prospective, longitudinal study comparing the use of WhatsApp messaging versus the SMART technique in patients with type 2 diabetes to improve treatment adherence
- Conditions
- Diabetes Mellitus, Type 2/Prevention & Control, Diabete Type 2, Treatment Adherence
- Trial name
- NCT07837856
- Testing
- Group I (WhatsApp) motivational and educational messages delivered periodically, Group II: To implement the SMART method
- Where
- Mexico
- Volunteers
- 250 people
- Sponsor
- Instituto Mexicano del Seguro Social
Hypercholesterolemia, Familial Hypercholesterolemia
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia.
- Trial name
- NCT05952856
- Testing
- Enlicitide Decanoate
- Where
- 168 sites in United States, Argentina and 12 more
- Volunteers
- 2,912 people
- Sponsor
- Merck Sharp & Dohme LLC
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- MOVE-Lp(a) (NCT07157774)
- Testing
- Muvalaplin
- Where
- 804 sites in United States, Argentina and 26 more
- Volunteers
- 10,450 people
- Sponsor
- Eli Lilly and Company
Renal Insufficiency, Chronic
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to < 45…
- Trial name
- NCT07624305
- Testing
- Balcinrenone/dapagliflozin, Dapagliflozin
- Where
- 478 sites in United States, Argentina and 25 more
- Volunteers
- 2,800 people
- Sponsor
- AstraZeneca
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hypertension, Pulmonary
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to…
- Trial name
- PATENT-CHILD (NCT02562235)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 16 sites in Colombia, Germany and 7 more
- Volunteers
- 24 people
- Sponsor
- Bayer
Anxiety Depression (Mild or Not Persistent)
Clinical Trials to Evaluate Neurophysiological and Neuropsychological Effects of a Mindfulness-based Intervention
Depression and anxiety are conditions with a high prevalence in the world population and youth are no exception. In developing countries it is reported that given the conditions of social disadvantage, anxiety and depression are…
- Trial name
- PRESENTE-IA (NCT06618339)
- Testing
- Mindfulness-based intervention
- Where
- Mexico
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de Baja California
Systemic Lupus Erythematosus
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18…
- Trial name
- APATURA (NCT05039840)
- Testing
- SAR441344 IV, SAR441344 SC
- Where
- 73 sites in United States, Argentina and 14 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Prostate Cancer
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after…
- Trial name
- PSMAcTION (NCT06780670)
- Testing
- Investigators choice of SoC, AAA817
- Where
- 93 sites in United States, Australia and 11 more
- Volunteers
- 443 people
- Sponsor
- Novartis Pharmaceuticals
Clear Cell Renal Cell Carcinoma
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is…
- Trial name
- CheckMate-67T (NCT04810078)
- Testing
- Nivolumab and rHuPH20, Nivolumab
- Where
- 89 sites in United States, Argentina and 15 more
- Volunteers
- 681 people
- Sponsor
- Bristol-Myers Squibb
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
- Trial name
- ATHENA-SSc-ILD (NCT05270668)
- Testing
- Tulisokibart, Companion diagnostic ( CDx)
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 154 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Solid Tumors
Avelumab Program Rollover Study
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
- Trial name
- NCT03815643
- Testing
- Avelumab
- Where
- 104 sites in United States, Argentina and 20 more
- Volunteers
- 205 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Asthma
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies.
- Trial name
- AIRPHRODITE (NCT06609239)
- Testing
- Lunsekimig
- Where
- 150 sites in United States, Argentina and 18 more
- Volunteers
- 900 people
- Sponsor
- Sanofi
Relapsing Multiple Sclerosis
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS.
- Trial name
- FENhance (NCT04586010)
- Testing
- Fenebrutinib, Teriflunomide
- Where
- 158 sites in United States, Argentina and 21 more
- Volunteers
- 746 people
- Sponsor
- Hoffmann-La Roche
Alcohol Use Disorder
A Non-Inferiority Trial of an Electronic vs Face-to-face Brief Intervention After Alcohol Screening in Two Countries
The goal of this clinical trial is to compare two different strategies to deliver brief interventions to people whose scores on the Alcohol Use Disorders Identification Test (AUDIT) suggest that their level of alcohol use may be…
- Trial name
- NCT07150156
- Testing
- brief intervention following alcohol screening
- Where
- 2 sites in Mexico, South Africa
- Volunteers
- 1,439 people, healthy volunteers welcome
- Sponsor
- HBSA
COPD, COPD Exacerbation
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
- Trial name
- TRITON (NCT04320342)
- Testing
- Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate
- Where
- 436 sites in United States, Argentina and 8 more
- Volunteers
- 3,406 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to…
- Trial name
- SHASTA-5 (NCT06880770)
- Testing
- Plozasiran
- Where
- 140 sites in United States, Argentina and 25 more
- Volunteers
- 288 people
- Sponsor
- Arrowhead Pharmaceuticals
Active Idiopathic Inflammatory Myopathy, Myositis
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM).
- Conditions
- Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis
- Trial name
- ALKIVIA (NCT05523167)
- Testing
- EFG PH20 SC, PBO
- Where
- 202 sites in United States, Argentina and 34 more
- Volunteers
- 265 people
- Sponsor
- argenx
End Stage Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Trial name
- POSIBIL6ESKD (NCT05485961)
- Testing
- CSL300
- Where
- 566 sites in United States, Argentina and 33 more
- Volunteers
- 3,110 people
- Sponsor
- CSL Behring
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.